KCNT2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21387528	0.49	2/20
SCHEMBL1476045	0.43	2/20
SCHEMBL22637576	1.00	1/20
SCHEMBL22637578	1.00	1/20
SCHEMBL24660636	1.00	1/20
SCHEMBL24660192	0.86	1/20
SCHEMBL24660543	0.86	1/20
SCHEMBL24660574	0.86	1/20
SCHEMBL24660722	0.86	1/20
SCHEMBL22637968	0.85	1/20
SCHEMBL22637970	0.85	1/20
SCHEMBL22637271	0.84	1/20
SCHEMBL22637275	0.84	1/20
SCHEMBL22637917	0.84	1/20
SCHEMBL22637922	0.84	1/20
SCHEMBL22637499	0.83	1/20
SCHEMBL22637501	0.83	1/20
SCHEMBL22637787	0.83	1/20
SCHEMBL22637792	0.83	1/20
SCHEMBL24660767	0.83	1/20

Clinical trials — most relevant to KCNT2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)	PHASE2/PHASE3	RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy	PHASE2	RECRUITING
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects	nan	RECRUITING
The Genetic Basis of Atrial Fibrillation (AF)	nan	COMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Long QT Syndrome-Population Genetics and Cardiac Studies	nan	COMPLETED
Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age	nan	RECRUITING
Comparing Direct vs Indirect Methods for Cascade Screening	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a KCNT2 binder may also engage these)

Protein	Name	Similarity
D3Z649	—	1.000	D3Z649 →
Q6UVM4	—	1.000	Q6UVM4 →
Q6ZPR4	—	0.997	Q6ZPR4 →
Q8QFV0	—	0.994	Q8QFV0 →
Q9Z258	—	0.992	Q9Z258 →
KCNT1	Potassium channel subfamily T member 1	0.988	landscape →
TRPC7	Short transient receptor potential channel 7	0.953	landscape →
Q9WVC5	—	0.949	Q9WVC5 →
Q8CJ19	—	0.949	Q8CJ19 →
G3MWR8	—	0.948	G3MWR8 →
Q99K70	—	0.944	Q99K70 →
Q91YD4	—	0.944	Q91YD4 →
Q3V1L4	—	0.943	Q3V1L4 →
O46411	—	0.943	O46411 →
Q8BWB6	—	0.942	Q8BWB6 →
E9PTA2	—	0.941	E9PTA2 →
D3ZMY7	—	0.940	D3ZMY7 →
Q7RTP6	—	0.940	Q7RTP6 →
NT5C2	Cytosolic purine 5'-nucleotidase	0.939	landscape →
Q5RA22	—	0.939	Q5RA22 →
Q5ZIZ4	—	0.939	Q5ZIZ4 →
A6QLE6	—	0.938	A6QLE6 →
Q9HB90	—	0.938	Q9HB90 →
NOX1	NADPH oxidase 1	0.937	landscape →
Q13635	—	0.936	Q13635 →
TRPC3	Short transient receptor potential channel 3	0.936	landscape →
Q8C5H1	—	0.936	Q8C5H1 →
Q12800	—	0.936	Q12800 →
Q9ERA0	—	0.936	Q9ERA0 →
F1QH17	—	0.936	F1QH17 →